Melixin

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Melixin

What is Melixin? Overview

Property Description
Active ingredient Meloxicam (INN)
Form Tablet, Suspension, Solution (Injectable)
Pharmacological class Nonsteroidal Anti-Inflammatory Drug (NSAID)
Common use Symptomatic relief of pain and inflammation
Origin Synthetic Compound (Oxicam derivative)

What Type of Medicine is Melixin?

Melixin is a specialized pharmaceutical preparation whose active ingredient is Meloxicam. It is formally classified as a Nonsteroidal Anti-Inflammatory Drug (NSAID), a primary group of medicines used to manage symptoms related to pain and inflammation. The substance is structurally identified as an Oxicam derivative and belongs to the enolic acid chemical group. Meloxicam is specifically noted for its mechanism as a preferential inhibitor of the COX-2 enzyme, which is the key pathway responsible for producing inflammatory compounds in the body. Meloxicam is clinically recognized for its efficacy as a long-acting analgesic and anti-inflammatory agent. This makes it suitable for providing continuous symptomatic treatment in scenarios requiring sustained relief from discomfort and swelling.


Composition and Origin: Is Meloxicam Synthetic?

The core component, Meloxicam (INN), is a synthetic compound that is not derived from natural sources; its precise chemical formula is C14H13N3O4S2. The drug product, Melixin, is a single-component product, meaning the therapeutic effect comes solely from the Meloxicam active ingredient. This active substance is formulated alongside various pharmaceutical excipients (such as binders and fillers) necessary to create the final dosage form. The development of Meloxicam as a synthetic compound ensures high purity and a reliable therapeutic profile for systemic use.


What Forms of Melixin Are Available?

Meloxicam is manufactured in several dosage forms for systemic action within the body. These often include the commonly used oral tablets and oral suspension, as well as specialized forms like an injectable solution for parenteral administration. This variety in drug forms offers flexibility in clinical application, contrasting with products only available in a single format. Meloxicam is classified as a prescription-only medication (Rx).

Regulatory References

  1. Meloxicam - LiverTox - NIH

What side effects are possible with Melixin?

Melixin: Possible Side Effects and Safety Information

This information is based strictly on official governmental regulatory documents (e.g., FDA, EMA) and covers documented adverse reactions and safety restrictions.

Serious and Clinically Significant Risks

Official safety profiles emphasize two potentially fatal risks that may occur at any time during treatment:

  1. Cardiovascular (CV) Thrombotic Events: Melixin can increase the risk of serious CV events, including myocardial infarction (heart attack) and stroke. This risk may increase with higher doses and longer durations of use. The drug is contraindicated for the treatment of pain right before or after coronary artery bypass graft (CABG) surgery.
  2. Gastrointestinal (GI) Adverse Events: The medicine carries a risk of serious, sometimes fatal, GI adverse events, such as bleeding, ulceration, and perforation of the stomach or intestines. This risk is higher in the elderly and those with a prior history of GI disease.

Common and Other Adverse Reactions

Adverse reactions documented in regulatory sources are classified by frequency. Common side effects (occurring in 1% to 10% of patients) include headache, dizziness, abdominal pain, diarrhea, nausea, vomiting, dyspepsia, and edema. Uncommon reactions include anemia, palpitations, increased blood pressure, and rash.

Serious, but Rare, adverse reactions include severe skin reactions (e.g., Stevens-Johnson syndrome, Toxic Epidermal Necrolysis), acute renal failure, and serious liver injury.

Safety Restrictions and Vulnerable Populations

To minimize risk, official documents recommend using the lowest effective dose for the shortest possible duration.

Contraindications also include patients with known hypersensitivity to the drug or other NSAIDs/Aspirin, and use is avoided in women starting around the 30th week of pregnancy due to the risk of fetal harm (premature closure of the ductus arteriosus). Use requires caution in patients with pre-existing conditions like severe heart failure or advanced renal disease.

Overdose and Emergency Response

Overdose Manifestations and When to Seek Help

The official regulatory profile for Melixin (Meloxicam) overdose describes a spectrum of potential outcomes that necessitate immediate medical intervention.

Mandated Emergency Action It is strictly mandated to seek medical attention immediately in the event of any suspected overdose or ingestion exceeding the prescribed amount. Urgent care is required if any severe or life-threatening manifestations are observed, reflecting the potential for acute systemic toxicity.

Documented Clinical Signs Classification Manifestations Listed in Regulatory Labeling
Common/Reversible Lethargy, drowsiness, nausea, vomiting, epigastric pain, and gastrointestinal bleeding.
Severe/Life-Threatening Acute renal failure, hepatic dysfunction, hypertension, respiratory depression, coma, convulsions, cardiovascular collapse, and cardiac arrest.

Official Management Strategy Management is centered on providing symptomatic and supportive care. The regulatory documentation states that no specific antidote for Meloxicam overdose is known. Interventions may include the administration of activated charcoal and Cholestyramine, which is documented to accelerate drug clearance. Continuous hospital monitoring and observation are required for patients who are severely symptomatic or where a substantial overdose is suspected.

Therapeutic Uses of Melixin

What Melixin Treats: Main Uses and Benefits

Melixin is commonly used to help with symptoms related to inflammatory or irritative states, focusing on conditions presenting with systemic or localized discomfort. The medication is relevant for easing the overall symptom burden in specific conditions, aiming to contribute to improved comfort and may assist with maintaining functional stability.


Key Therapeutic Applications

Melixin is commonly used for the long-term symptomatic management of established chronic conditions like osteoarthritis (OA), rheumatoid arthritis (RA), and juvenile idiopathic arthritis (JIA). It is also relevant for easing symptoms in specific inflammatory conditions of the spine, such as ankylosing spondylitis, and may assist with managing moderate-to-severe pain in certain post-operative recovery scenarios. The medication is relevant for managing symptom clusters that include joint pain, tenderness, and stiffness.

“The medication may be part of symptomatic management that helps ease the overall symptom burden associated with these long-term conditions.”

This medication helps address symptoms that may interfere with daily functioning, particularly during phases when they become more noticeable.


Quick Fact: Supportive relief for Joint Pain and Swelling

Regulatory References

  1. NIH DailyMed/FDA Label for Meloxicam

Eligibility and Restrictions for Use

Eligibility Scope

The eligibility for Melixin use is strictly defined by regulatory bodies based on age, physiological status, and underlying medical conditions.

Eligibility Classification Population Group Regulatory Status
Approved Use Adults Established
Approved Use Pediatric patients (2 years and older) Established for JRA
Contraindicated History of aspirin/NSAID allergy Absolute Prohibition
Contraindicated Patients after CABG surgery Absolute Prohibition
Contraindicated Severe heart failure or severe, non-dialysed renal/hepatic impairment Absolute Prohibition
Contraindicated Pregnancy ge 30 weeks gestation Absolute Prohibition
Restricted Use Severe renal failure on hemodialysis Maximum dose 7.5 mg

Official documents indicate the medicine is generally approved for adults and children aged 2 years and older for specific arthritic indications. However, use is contraindicated in multiple populations, including those with a history of allergic reactions to NSAIDs and individuals with severe pre-existing organ dysfunction (liver, kidney, heart). Furthermore, the medicine is contraindicated during the third trimester of pregnancy. Use in older adults is permitted but requires caution, while its use during breastfeeding is generally not recommended.

What should I know about interactions with other medicines?

Melixin Interactions with other medicines and products

This section outlines officially documented interaction patterns for Melixin (Meloxicam), as specified in governmental regulatory labeling. This information details which combinations are restricted or require monitoring based on established regulatory constraints.


Contraindicated and High-Risk Combinations

Melixin is contraindicated in patients with a history of allergic-type reactions (such as asthma or urticaria) after taking Aspirin or other NSAIDs. It is also prohibited for use in the setting of peri-operative pain for Coronary Artery Bypass Graft (CABG) surgery. Additionally, the Melixin Oral Suspension is contraindicated with Sodium Polystyrene Sulfonate (Kayexalate) due to the risk of intestinal necrosis.


Documented Interaction Categories

Interaction Type Interacting Agents / Classes
Increased Bleeding Risk Anticoagulants (e.g., Warfarin), Antiplatelets, SSRIs/SNRIs, and other NSAIDs or analgesic doses of Aspirin.
Reduced Efficacy of Co-treatment ACE Inhibitors, ARBs, Beta-Blockers, and Diuretics (may diminish antihypertensive or natriuretic effects).
Altered Drug Exposure Methotrexate (Melixin increases plasma levels); Cholestyramine (accelerates Melixin clearance); and CYP2C9 Inhibitors (may increase Meloxicam levels).
Toxicity Risk Lithium (Melixin increases plasma levels) and Cyclosporine (increased nephrotoxicity risk).

Regulatory documents note that the risk of renal function deterioration when combining Melixin with ACE Inhibitors/ARBs is heightened in elderly or volume-depleted patients.

Mechanism of Action

Melixin's mechanism is defined by its targeted biochemical intervention in the pathways that generate inflammatory signals, derived solely from the action of its single active component, Meloxicam.

Preferential Inhibition of the COX-2 Enzyme System

The molecule initiates its action by exhibiting preferential inhibition of the Cyclooxygenase-2 ( COX-2) enzyme. COX-2 is the inducible isoform whose expression increases in response to stimuli. This specific targeting inactivates the enzyme, which prevents the production of pro-inflammatory mediators.

Modulation of Prostaglandin Synthesis and Signaling

By blocking COX-2, Melixin interrupts the Arachidonic Acid Pathway , thereby curtailing the cellular synthesis of prostaglandins (such as PGE2). Prostaglandins are lipid mediators that influence nociceptive signaling, localized vascular tone, and central thermoregulation. The resultant reduction in these mediators modulates peripheral pain signal transmission and central thermoregulatory pathways.

Mechanistic Selectivity and Functional Constraint

The mechanism features mechanistic selectivity, favoring COX-2 over the homeostatic COX-1 enzyme, which is involved in basal physiological processes. However, the mechanism is functionally constrained from robustly inhibiting platelet aggregation, as it only minimally affects Thromboxane A2 synthesis.

Dosage and Administration Information

The administration of Melixin is standardized across its available routes to ensure consistent usage. The medicine is approved for administration via the oral route (tablets and suspension) and as an intravenous (IV) injection for systemic action.

Standard dosing schedules are based on a single daily dose (q.d.) for all adult regimens. For oral use, the typical starting dose is 7.5 mg once daily, with the established maximum daily dose being 15 mg. The maximum 15 mg limit must not be exceeded. The IV injection is typically dosed at 30 mg once daily for a short duration, serving as a bridge to oral therapy.

The administration context includes specific procedural rules. Oral forms can generally be taken with or without food; however, the oral suspension must be shaken well prior to measurement. The IV solution is administered as a bolus injection over a minimum specified period, such as at least 15 seconds. Dose adjustments are specified for specific populations: older or high-risk patients should begin treatment at the 7.5 mg starting dose, and patients undergoing hemodialysis have a maximum daily dose of 7.5 mg. If a dose is missed, patients should take the next scheduled dose at the usual time and should not take a double dose to compensate.

Recent Clinical Evidence

Research evidence / Overview of studies

Evidence for Chronic Lower Back Pain (CLBP)

Clinical research has explored whether outcomes in adults with chronic lower back pain (CLBP) are affected by this treatment. The majority of published data is derived from randomized controlled trials (RCTs) and comprehensive meta-analyses.


Key Findings on Efficacy and Evidence

Study Investigation

One study investigated the observed effects by examining the underlying inflammatory components of CLBP. This research used biomarkers to observe changes in inflammatory signaling pathways among study participants. The studies evaluated the reported changes in pain and functional disability as key outcomes.

Pooled Data Analysis

A comprehensive meta-analysis suggests that some studies reported a reduction in pain scores maintained for up to 6 months. This analysis focused on pooling data from trials that employed similar outcome measures, such as the Visual Analog Scale (VAS) for pain.

Comparative Exploration

A comparative study examined the outcomes when this therapy was used alone versus in combination with another treatment. The study observed different reported outcomes between the two groups.


Phase II Trial and Specific Indications

In a small Phase II trial, changes in acute symptoms were observed among participants receiving the drug.

Specific Indications and Trial Protocol

The effect of the specific formulation was explored in relation to neuropathic pain in a separate research arm.


Limitations and Exclusions

Clinical suitability was not a focus of the studies reviewed. Patients with pre-existing kidney or liver conditions may have been excluded from the study populations to isolate the primary effects of the treatment.

The studies reviewed focused exclusively on the use of this treatment for chronic lower back pain. Off-label use was not examined. The evidence base for this treatment is concentrated on adult patients, with limited data available for pediatric or geriatric populations.

Key Studies & References

  1. Meloxicam - LiverTox - NCBI Bookshelf (NIH)

Frequently Asked Questions (FAQ)

Common questions about Melixin (FAQ)

Q: How long does it typically take before Melixin starts working?

Melixin is not intended to provide immediate relief, as its action begins over time. According to the official product information, the active ingredient typically reaches its highest concentration in the bloodstream approximately 5 to 6 hours after an oral dose is taken. This measurement of time to reach maximum effect is referred to as Tmax in clinical documents.

Q: Will Melixin help me feel better immediately?

The medicine is designed for sustained relief and generally does not provide immediate symptomatic improvement. Official documentation indicates that the full effects may not be felt right away because it takes several hours for the active component to reach its maximum concentration in your body.

Q: Can I take Melixin with my daily vitamins or supplements?

Regulatory documents and official drug information advise caution regarding the combination of any medicine with vitamins, supplements, or herbal products. This guidance is provided because certain non-prescription products may potentially interact with prescription medication. For clarification, consulting a healthcare provider is generally recommended.

Q: Is Melixin known to cause weight gain?

Weight gain is listed as a potential adverse reaction in the consumer information provided by certain regulatory bodies. Additionally, official safety documents list ankle swelling, known clinically as edema, as a common side effect of this medicine. Any unexpected changes in weight can be reviewed with a healthcare provider.

Q: How long does Melixin stay in your system after stopping it?

The rate at which the active ingredient is removed from the body is addressed in official documents. The plasma elimination half-life is listed as approximately 20 hours. The half-life refers to the time it takes for the concentration of the medicine in the bloodstream to be reduced by half.

Q: Is Melixin addictive or habit-forming?

Melixin is classified as a nonsteroidal anti-inflammatory drug (NSAID). This drug class is generally not considered habit-forming. Regulatory bodies do not classify this medicine as a narcotic or a controlled substance.

Q: Can Melixin affect my sleep?

Official labeling documents do not commonly list general sleepiness (somnolence) as a frequent side effect, but side effects such as fatigue and, in rare instances, insomnia have been reported. Sleep disturbances are a topic that can be addressed with a healthcare professional.

Q: Does Melixin have a warning about driving or operating machinery?

The official product information advises caution regarding driving and operating machinery. This is due to common side effects such as dizziness and headache that may occur with this medicine. Official documentation notes that patients experiencing these effects are typically advised to use caution.

Q: What does 'contraindication' mean in relation to Melixin?

A contraindication is a critical regulatory term defined in official documents. It describes a specific condition or factor that serves as a reason to withhold a certain medical treatment because the potential for harm outweighs any possible benefit. For Melixin, contraindications include certain allergies and specific heart conditions.

Q: Does Melixin cause changes in mood or anxiety?

While not frequently reported, some product monographs list altered mood, depression, or mental confusion as rare or infrequent adverse reactions. Official documentation notes these reports as part of the possible adverse events experienced by patients.

Q: Has Melixin been recently approved by the FDA or EMA?

Regulatory records indicate that the original active ingredient, Meloxicam, received approval from major agencies, like the FDA, in the early 2000s. Since then, various generic versions and different formulations of the medicine have been approved at later dates.

Q: What happens if I stop taking Melixin suddenly?

Official drug labeling documents recommend against making abrupt changes to any prescribed treatment regimen. Consultation with a healthcare provider is generally recommended before making changes to a prescribed regimen, especially for chronic use.

Q: Does Melixin require any special monitoring or blood tests?

Official regulatory documents specify that monitoring of renal (kidney) and liver functions should be performed for certain patients. This testing is recommended particularly for older or high-risk individuals due to the potential for adverse effects on these organs.

Q: I heard Melixin is metabolized by the liver—what does that mean?

The term metabolized refers to how the body processes the drug. According to the product information, the active ingredient is extensively broken down, or metabolized, primarily by enzymes in the liver. The inactive components of the drug are then cleared from the body through the kidneys and feces.

Q: Is there a generic version of Melixin available?

Yes, regulatory bodies around the world have approved generic versions of the active ingredient, Meloxicam. These generics are considered bioequivalent to the original product, meaning they meet the required standards for having the same chemical action in the body.

Q: Is it normal if the effect of Melixin seems to wear off quickly?

Melixin is typically prescribed as a once-daily dose, designed to provide sustained relief throughout the day. If you notice that the effect seems to wear off significantly before the next scheduled dose, official guidance indicates that a concern about the duration of effect is a topic that can be reviewed with a healthcare provider regarding the prescribed regimen.

Q: What does the patient leaflet say about taking Melixin with alcohol?

Official warnings in product information and patient leaflets state that combining this medication with alcoholic beverages is not recommended. This restriction is in place because alcohol consumption may increase the risk of serious stomach and intestinal bleeding while taking this medicine.

Q: Are there any common misuses of Melixin that I should be aware of?

Regulatory documents caution against one specific misuse, which is exceeding the maximum recommended daily dose. Official information emphasizes that doing so can significantly increase the risk of serious cardiovascular (heart) and gastrointestinal (stomach/intestine) side effects.

Q: Does Melixin affect fertility?

Official regulatory documents note that the medicine is generally not recommended for women trying to conceive. Its mechanism of action may temporarily affect female fertility. Stopping the medicine should be considered for women who are having difficulty getting pregnant.

How should Melixin be stored and disposed of?

Official Storage and Disposal Requirements

Official regulatory documents define strict conditions for the storage and disposal of Melixin (Meloxicam) to maintain product integrity and safety.

Requirement Official Instruction
Storage Temperature Store at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F) [Source 2.7].
Protection Keep away from heat, moisture, and direct light; keep from freezing [Source 2.5].
Packaging Store in a closed, tight container and keep in the container it came in (original packaging) [Source 2.7].
Child Safety Keep this and all medications out of the reach of children [Source 2.7].
Disposal Do not keep outdated medicine [Source 2.5]. Disposal must follow local regulations or a drug take-back program. Do not allow to enter surface water or drains [Source 3.6].

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Melixin found in:

A-Z Index: